NCT02077569 - AKT Inhibitor in Oestrogen Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 21, 2017

Study Completion Date

February 21, 2017

Conditions

Invasive Breast Cancer

Interventions

DRUG

AZD5363

Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)

Trial Locations (11)

DE22 3DT

Royal Derby Hospital, Derby

PL6 8DH

Plymouth Hospitals NHS Trust, Derriford, Plymouth

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

BH15 2JB

Poole Hospital NHS Foundation Trust, Poole

LE1 5WW

Leicester Royal Infirmary, Leicester

EH4 2XU

Western General Hospital, Edinburgh

L7 8XP

Royal Liverpool University Hospital, Liverpool

NG17 4JL

Kingsmill Hospital, Sutton in Ashfield

S10 2SJ

Sheffield Cancer Research Centre, Sheffield

B15 2TT

University Hospital Birmingahm, Birmingham

LS9 7TF

Leeds St James Institue of Oncology, Leeds